Zobrazeno 11 - 20
of 84
pro vyhledávání: '"329"'
Publikováno v:
Blood. 110:1310-1310
Syk kinase is central to FcR and B-cell signaling in inflammatory cells. By inhibiting syk, and thereby IgG signaling, R788 (a small molecule prodrug for biologically active R406), inhibits the downstream activation of mast cells, macrophages and B-c
Autor:
Franco Locatelli, Tommaso Stefanelli, Valkal Bhatt, Shashikant Apte, Nada Hamad, Stephanie J. Lee, Francesca Bonifazi, Takanori Teshima, Jackie Han, Kentaro Fukushima, Maanasa Gowda, Ivan S. Moiseev, Juan Carlos Vallejo Llamas, Joseph Pidala, Francis Ayuk, Robert Zeiser, Tsila Zuckerman, Mike Zuurman
Publikováno v:
Blood. 138:3909-3909
BACKGROUND Approximately 50% of patients (pts) who receive initial cGVHD therapy are steroid refractory or dependent (SR/D); standard second-line therapy has yet to be established. Quality of life (QOL) in these pts is poor and worsens with disease s
Autor:
Yanmin Zhao, Lizhen Liu, Yi Chen, Ying Lu, Jian Yu, Kang Yu, He Huang, Xiaoyu Lai, Jimin Shi, Huarui Fu, Fei Gao, Baodong Ye, Lieguang Chen, Jianping Lan, Xiaolu Song, Yi Luo
Publikováno v:
Blood. 138:1825-1825
Objective Hematopoietic stem cell transplantation (HSCT) is one of the most efficient treatments for hematologic malignancies. However, relapse remains the main cause of transplant failure. In myeloid neoplasia, the long-term survival for patients wh
Publikováno v:
Blood. 138:1944-1944
Background: Rapid advances in the understanding of the biology of MDS and AML have led to novel therapeutic interventions that have increased the clinical complexity of decision making in patient care. This study sought to quantify professional pract
Autor:
Mengyang Di, Xiaomei Ma, Rong Wang, Scott F. Huntington, Natalia Neparidze, Rory M. Shallis, Nikolai A. Podoltsev, Amer M. Zeidan
Publikováno v:
Blood. 138:282-282
Introduction: Patients (pts) with chronic-phase chronic myeloid leukemia (CML) are recommended to have quantitative BCR-ABL1 polymerase chain reaction (qPCR) testing every 3 months (mo) during the 1 st year of tyrosine kinase inhibitor (TKI) treatmen
Autor:
Jian-Ping Zhang, Rui-Juan Sun, Peihua Lu, Junfang Yang, Xian Zhang, Yan-Li Zhao, Jingjing Li, Min Xiong, Jia-Rui Zhou, De-Yan Liu, Yue Lu, Xing-Yu Cao, Zhi-Jie Wei
Publikováno v:
Blood. 136:40-41
Introduction Current available treatments are limited once patients with B-ALL relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT). While chimeric antigen receptor (CAR) T-cell therapy offers a chance of remission, long-t
Autor:
Shanta Chawla, Manuel Modiano, Jayaram S. Bharadwaj, Jawad Francis, Hlalah Osama, Lee S. Schwartzberg, Nishan Tchekmedyian, Francois Lebel, Gajanan Bhat
Publikováno v:
Blood. 136:34-35
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Rohtesh S. Mehta, Gregory P. Kaufman, Elisabet E. Manasanch, Neeraj Saini, Chitra Hosing, Uday R. Popat, Qaiser Bashir, Gabriela Rondon, Elizabeth J. Shpall, Partow Kebriaei, Krina K. Patel, May Daher, Ruby Delgado, Muzaffar H. Qazilbash, Stefan O. Ciurea, Yago Nieto, Issa F. Khouri, Samer A. Srour, Denái R. Milton, Robert Z. Orlowski, Richard E. Champlin, Hans C. Lee
Publikováno v:
Blood. 136:24-25
Introduction The role of upfront autologous stem cell transplantation (ASCT) for multiple myeloma (MM) has evolved over the last three decades, with significant improvements in preparative regimen, supportive care, induction, and maintenance therapy.
Publikováno v:
Blood. 136:14-15
Introduction: Management of acute venous thromboembolism (VTE) in patients with chronic liver diseases is challenging due to the risk of bleeding and thrombotic complications. No clinical trials have studied vitamin K antagonists (VKA) or low molecul
Autor:
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Christopher R. Flowers, Jeffrey M. Switchenko
Publikováno v:
Blood. 134:3416-3416
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease. Patients exhibit a 30%-40% relapse/refractory rate on standard first-line therapy and are known to have poor outcomes with relapsed/refractory disease, indicating a